1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
Sumitomo Dainippon Pharma said on June 4 that it will launch its atypical antipsychotic Latuda (lurasidone), already a blockbuster overseas, on June 11 for the treatment of schizophrenia and bipolar depression. The Osaka drug maker projects Japan sales of 2.2…
To read the full story
Related Article
- After 3rd PIII Try, Sumitomo Dainippon Finally Files Latuda for Japan Approval
August 1, 2019
- Latuda Succeeds in PIII Schizophrenia Study, Japan NDA Submission Planned by September
January 11, 2019
- Sumitomo Dainippon to Begin Lurasidone PIII within FY2015, 3rd Attempt for Schizophrenia Indication
December 10, 2015
- Sumitomo Dainippon to Take Yet Another Stab at Lurasidone PIII for Schizophrenia
October 29, 2015
- Sumitomo Dainippon Faces Dim Prospects for Lurasidone Filing in Japan
April 27, 2015
- Sumitomo Dainippon Aims to File Lurasidone in Japan in FY2015 following Favorable Asian PIII Study Results
December 26, 2014
BUSINESS
- J&J to Terminate Business with Wholesaler Toho
February 25, 2025
- Antibiotic Fetroja Approved in South Korea: Shionogi
February 25, 2025
- Mitsubishi Tanabe’s Parkinson’s Drug Accepted for EMA Review
February 25, 2025
- Eisai Limits ALS Drug Shipment on Unexpectedly High Demand
February 21, 2025
- Kaken Set to Take Stab at US Market with Vascular Malformation Drug
February 20, 2025
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…